CD274 and non-small cell lung carcinoma: However, accumulating evidence suggests that programmed death ligand 1 (PD-L1)+ TAMs in tumors could better predict a patient’s response to immunotherapy than PD-L1− TAMs in non-small-cell lung cancer patients [10, 11].